Alnylam Pharmaceuticals
ALNY
#624
Rank
NZ$56.49 B
Marketcap
$436.40
Share price
-0.16%
Change (1 day)
74.30%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$7.16. In 2022 the company made an earnings per share (EPS) of -$16.18 a decrease over its 2021 EPS that were of -$12.54.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.55-59.49%
2022-$16.1829.03%
2021-$12.54-3.36%
2020-$12.97-8.48%
2019-$14.187.67%
2018-$13.1739.74%
2017-$9.4212.94%
2016-$8.3438.84%
2015-$6.01-32.88%
2014-$8.95259.44%
2013-$2.49-31.25%
2012-$3.6252.94%
2011-$2.3730.77%
2010-$1.81-8.77%
2009-$1.9978.13%
2008-$1.11-70.78%
2007-$3.8199.09%
2006-$1.92-43.88%
2005-$3.41-82.33%
2004-$19.32-59.23%
2003-$47.39

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.96-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$65.06-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.64 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.47-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.94-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.51-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.54-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.48-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel